You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

SUPRENZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Suprenza patents expire, and what generic alternatives are available?

Suprenza is a drug marketed by Citius Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has two patent family members in two countries.

The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.

Paragraph IV (Patent) Challenges for SUPRENZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SUPRENZA Orally Disintegrating Tablets phentermine hydrochloride 37.5 mg 202088 1 2013-03-22
SUPRENZA Orally Disintegrating Tablets phentermine hydrochloride 15 mg and 30 mg 202088 1 2012-10-19

US Patents and Regulatory Information for SUPRENZA

SUPRENZA is protected by one US patents.

Patents protecting SUPRENZA

Orally disintegrating tablets with speckled appearance
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUPRENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 ⤷  Try a Trial ⤷  Try a Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 ⤷  Try a Trial ⤷  Try a Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SUPRENZA

See the table below for patents covering SUPRENZA around the world.

Country Patent Number Title Estimated Expiration
Spain 2263216 ⤷  Try a Trial
European Patent Office 1001748 PROCEDE DE PREPARATION DE GRANULES SERVANT A PRODUIRE DES COMPRIMES SOLUBLES DANS LA BOUCHE A DESINTEGRATION RAPIDE (A PROCESS FOR THE PREPARATION OF A GRANULATE SUITABLE TO THE PREPARATION OF RAPIDLY DISINTEGRABLE MOUTH-SOLUBLE TABLETS) ⤷  Try a Trial
Japan 2001510785 ⤷  Try a Trial
Australia 8977698 ⤷  Try a Trial
Japan 4947833 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 9904758 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SUPRENZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2317997 2190050-1 Sweden ⤷  Try a Trial PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.